Chimerix Expects Dordaviprone Interim Overall Survival Data In 2025 And Final OS Data In 2026
Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP.